Star Therapeutics

While innovation in other #bleedingdisorders has advanced rapidly, innovation in VWD has lagged behind for decades. As we close out Bleeding Disorders Awareness Month, patients Heather & Z share a message of hope for innovation for the VWD community.

It was a great day at @NewEnglandHemo's Consumer Medical Symposium! We had valuable conversations with members of the bleeding disorders community & shared more on VGA039 during the industry roundtable. Thanks to NEHA for bringing the community together!

That's a wrap on #THSNA26! We thank Dr. Niki Machin for presenting our VGA039 Ph 1/2 multi-dose study data in an oral presentation, are grateful for the chance to connect with our amazing peers in the #bleedingdisorders space & felt energized by advances planned in 2026.

"It's the pain of being dismissed, the exhaustion of being misdiagnosed." March is Bleeding Disorders Awareness Month. VWD is unlike other bleeding disorders and deserves recognition as such. Listen as VWD Alliance's Sunny Maini shares his experience living with VWD.

Rare ≠ Invisible Rare diseases are often misunderstood or dismissed, leaving patients to navigate delayed diagnoses & limited treatment options. We stand with the bleeding disorders community & remain dedicated to advancing science for diagnoses that deserve recognition & care.

Those with #VWD often face a lifetime of challenges that are not only physical but emotional: feeling isolated, excluded & exhausted. If you or a loved one are interested in learning if you may qualify for our Phase 3 study in all types of VWD, click here: research.leapcure.com/studies/vwdcli…

At Star, we believe science is most powerful when it is driven by purpose: grounded in patients’ lived experiences and focused on creating tangible impact. We're proud to work alongside women at Star and the broader scientific community who are helping advance care. #IDWGS♀️

We're looking forward to #EAHAD2026 & sharing the latest on VGA039 through 2 oral presentations. These talks reflect ongoing progress & our commitment to advancing innovation for the VWD community. We're grateful to our presenters & investigators for their dedication to patients.

Today is VWD Awareness Day in Europe. Patient stories highlight why awareness, education & treatment innovation are critical. Many people with VWD face dismissed symptoms & a need to advocate for better care. Insight from @EHC_Haemophilia VWD Committee Co-Chair Dr. Jo Traunter⬇️

“It just felt like I was never going to stop bleeding." Kerri’s #VWD story reflects the burden many patients carry relying on regular IV infusions, yet still struggling to find relief. Her story reinforces the need for new therapies that can transform care for all VWD patients.

The mental toll of living with #VWD can be just as heavy as the physical one. We’re studying an investigational therapy that can be given once monthly as an injection under the skin in patients who are 12-75 w/ any type of VWD. Explore initial eligibility: research.leapcure.com/studies/vwdcli…

Thanks to everyone who joined us for CEO Adam Rosenthal’s corporate update at #JPM26 this week. We're grateful for the chance to connect with partners and friends as we head into another year of advancing care for people living with #bleedingdisorders like von Willebrand Disease.

We're presenting at #JPM26 next week, where we'll share more about Star's progress in #vonWillebrandDisease. We hope to see many of you attending the conference in person and look forward to kicking off 2026 together. star-therapeutics.com/star-therapeut…

#vonWillebrandDisease is often overlooked compared to other #bleedingdisorders like hemophilia, leaving many patients without the resources & support they deserve. Listen as Nick shares his experience with a condition that was frequently misunderstood and the toll it's taken.

If you or someone you know has been diagnosed with #VonWillebrandDisease, we want to connect with you. Our VIVID (VGA039 Investigation in Von Willebrand Disease) Phase 3 clinical trial is now enrolling patients with any type of VWD aged 12-75. Learn more: star-therapeutics.com/vega-program/

A new @LEK_Consulting paper reinforces what some have long understood: VWD is the most common bleeding disorder & is deeply underserved. Innovation in VWD represents a significant growth opportunity given the patient population & low competitive intensity. lek.com/insights/hea/u…

We’re working to give a voice to patients with #vonWillebrandDisease, a #bleedingdisorder community that has too often felt unheard. Hear CEO Adam Rosenthal share insights with @BiotechTV on our Phase 1/2 VGA039 data, where all patients had substantial bleed reductions. #ASH25

Today at #ASH25, we’re excited to announce interim Ph 1/2 data for VGA039 showing substantial bleed reductions in #vonWillebrandDisease with a once monthly subcutaneous dose. CMO Gary Patou shares insight into our commitment to innovation in #VWD. More: star-therapeutics.com/star-therapeut…

As a parent, your child’s health is paramount. For Kari, facing a #vWD diagnosis for both herself & daughter Kayla felt overwhelming. This #FamilyCaregiversMonth, they're shedding light on the genetic component of many #bleedingdisorders & sharing hope. #FamilyHistoryDay

Last weekend, we joined the @nbd_foundation at the Unite Walk to advocate for improved care. We're deeply dedicated to supporting those affected by bleeding disorders through research, funds, & advocacy. Congrats to NCBDF for rallying the community at another empowering event!